AR127006A1 - UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc - Google Patents
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN FcInfo
- Publication number
- AR127006A1 AR127006A1 ARP220102429A ARP220102429A AR127006A1 AR 127006 A1 AR127006 A1 AR 127006A1 AR P220102429 A ARP220102429 A AR P220102429A AR P220102429 A ARP220102429 A AR P220102429A AR 127006 A1 AR127006 A1 AR 127006A1
- Authority
- AR
- Argentina
- Prior art keywords
- sample
- peptides
- quantifying
- liquid chromatography
- antibodies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan métodos sin cromatografía líquida para cuantificar una proteína diana en una muestra. Una forma de realización proporciona un método sin cromatografía líquida para cuantificar anticuerpos diana en una muestra que incluye las etapas de agregar a la muestra un anticuerpo estándar interno etiquetado, digerir los anticuerpos en la muestra para producir péptidos, fraccionar los péptidos; y cuantificar los anticuerpos diana mediante el uso de un sistema MS2 de infusión directa que contiene una o más trampas de iones y dos o más filtros de masas cuadripolares y un ionizador de electropulverización, en donde el método no comprende cromatografía líquida. Reivindicación 1: Un método sin cromatografía líquida para cuantificar anticuerpos diana en una muestra que comprende: agregar a la muestra un anticuerpo estándar interno etiquetado; digerir los anticuerpos de la muestra para producir péptidos; fraccionar los péptidos; y cuantificar los anticuerpos diana mediante el uso de un sistema MS2 de infusión directa que contiene una o más trampas de iones y dos o más filtros de masas cuadripolares y un ionizador de electropulverización, en donde el método no comprende cromatografía líquida. Reivindicación 9: Un método para cuantificar un producto de fármaco de proteína en una muestra biológica que comprende: agregar a la muestra una cantidad conocida de un péptido sustituto etiquetado con masa pesada que tiene una secuencia de aminoácidos de acuerdo con SEQ ID Nº 1; digerir el producto de fármaco de proteína de la muestra en péptidos; fraccionar los péptidos en condiciones que retengan péptidos que tengan una secuencia de aminoácidos de acuerdo con la SEQ ID Nº 1; analizar la muestra que contiene los péptidos con producto de fármaco de proteína y los péptidos sustitutos para la presencia del péptido que tiene una secuencia de aminoácido de acuerdo con SEQ ID Nº 1 mediante el uso de un sistema MS2 para calibrar el sistema, en donde el sistema MS2 comprende una o más trampas de iones y dos o más filtros de masas cuadripolares y un ionizador de electropulverización, y cuantificar la cantidad de producto de fármaco de proteína presente en la muestra en función de la presencia del péptido, en donde el método no utiliza la cromatografía líquida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241593P | 2021-09-08 | 2021-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127006A1 true AR127006A1 (es) | 2023-12-06 |
Family
ID=83995567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102429A AR127006A1 (es) | 2021-09-08 | 2022-09-08 | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230077710A1 (es) |
| AR (1) | AR127006A1 (es) |
| TW (1) | TW202326138A (es) |
| WO (1) | WO2023039457A1 (es) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| HRP20120175T1 (hr) | 2006-06-02 | 2012-03-31 | Regeneron Pharmaceuticals | Antitijela s visokim afinitetom za humani il-6 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2178916T3 (pl) | 2007-07-31 | 2015-08-31 | Regeneron Pharma | Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| IL283424B2 (en) | 2010-10-06 | 2023-09-01 | Regeneron Pharma | Stabilized formulations that include antibodies against the interleukin receptor (il-4r) |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US8679767B2 (en) * | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| EA033387B1 (ru) | 2012-01-23 | 2019-10-31 | Regeneron Pharma | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| JP6309521B2 (ja) | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| EA034834B1 (ru) | 2013-03-15 | 2020-03-26 | Ридженерон Фармасьютикалз, Инк. | Антагонисты il-33 и их применение |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| AU2015229591B2 (en) | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SG10202003996YA (en) | 2014-05-05 | 2020-06-29 | Regeneron Pharma | Humanized c5 and c3 animals |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| AU2015317899A1 (en) | 2014-09-16 | 2017-04-06 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| EP3906249A1 (en) * | 2019-12-06 | 2021-11-10 | Regeneron Pharmacetucals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| EP4162250A4 (en) * | 2020-06-09 | 2024-10-23 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies |
-
2022
- 2022-09-08 AR ARP220102429A patent/AR127006A1/es not_active Application Discontinuation
- 2022-09-08 TW TW111134041A patent/TW202326138A/zh unknown
- 2022-09-08 WO PCT/US2022/076089 patent/WO2023039457A1/en not_active Ceased
- 2022-09-08 US US17/930,471 patent/US20230077710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202326138A (zh) | 2023-07-01 |
| US20230077710A1 (en) | 2023-03-16 |
| WO2023039457A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system | |
| Steen et al. | Detection of tyrosine phosphorylated peptides by precursor ion scanning quadrupole TOF mass spectrometry in positive ion mode | |
| Johnson et al. | Combination of FAIMS, protein A depletion, and native digest conditions enables deep proteomic profiling of host cell proteins in monoclonal antibodies | |
| Kadek et al. | Aspartic protease nepenthesin-1 as a tool for digestion in hydrogen/deuterium exchange mass spectrometry | |
| Bendall et al. | An enhanced mass spectrometry approach reveals human embryonic stem cell growth factors in culture | |
| Heudi et al. | Towards absolute quantification of therapeutic monoclonal antibody in serum by LC− MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry | |
| Kim et al. | In-source fragmentation and the sources of partially tryptic peptides in shotgun proteomics | |
| Crowe et al. | Ubiquitin chain enrichment middle-down mass spectrometry enables characterization of branched ubiquitin chains in cellulo | |
| Buchberger et al. | Advances in mass spectrometric tools for probing neuropeptides | |
| Wakabayashi et al. | Phosphoproteome analysis of formalin-fixed and paraffin-embedded tissue sections mounted on microscope slides | |
| CN105518447B (zh) | 肽片段的制备方法及该方法中使用的肽片段制备用试剂盒、以及分析方法 | |
| Zhai et al. | Systematic research on the pretreatment of peptides for quantitative proteomics using a C 18 microcolumn | |
| JP2019507341A5 (es) | ||
| Sun et al. | Capillary zone electrophoresis-electrospray ionization-tandem mass spectrometry for quantitative parallel reaction monitoring of peptide abundance and single-shot proteomic analysis of a human cell line | |
| KR20210153102A (ko) | 숙주세포 단백질의 확인 | |
| Zhu et al. | Absolute quantitation of host cell proteins in recombinant human monoclonal antibodies with an automated CZE‐ESI‐MS/MS system | |
| Strasser et al. | Proteomic profiling of IgG1 producing CHO cells using LC/LC-SPS-MS3: the effects of bioprocessing conditions on productivity and product quality | |
| Samgina et al. | EThcD discrimination of isomeric leucine/isoleucine residues in sequencing of the intact skin frog peptides with intramolecular disulfide bond | |
| Huang et al. | Automatic disulfide bond assignment using a1 ion screening by mass spectrometry for structural characterization of protein pharmaceuticals | |
| Kline et al. | Improved label-free quantification of intact proteoforms using field asymmetric ion mobility spectrometry | |
| CN103884807B (zh) | 一种18o在线标记的蛋白质定量分析平台及其操作方法 | |
| Grgic et al. | MALDI MSI Protocol for Spatial Bottom-Up Proteomics at Single-Cell Resolution | |
| Hauser et al. | Online microwave D-cleavage LC-ESI-MS/MS of intact proteins: site-specific cleavages at aspartic acid residues and disulfide bonds | |
| Loo et al. | Proteomics in molecular diagnosis: typing of amyloidosis | |
| AR127006A1 (es) | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |